International journal of clinical oncology
-
Int. J. Clin. Oncol. · Feb 2013
Paclitaxel-induced peripheral neuropathy in patients receiving adjuvant chemotherapy for breast cancer.
The long-term outcomes and risk factors of paclitaxel-induced peripheral neuropathy (PIPN) have not yet been fully elucidated. ⋯ PIPN persists longer in older patients and in those who experience severe neuropathy. Further studies to identify the risk factors for PIPN are warranted.
-
Int. J. Clin. Oncol. · Feb 2013
Can docetaxel therapy improve overall survival from primary therapy compared with androgen-deprivation therapy alone in Japanese patients with castration-resistant prostate cancer? A multi-institutional cooperative study.
To verify the actual clinical benefit of docetaxel (DOC) therapy and to explore the prognostic factors that may predict overall survival in Japanese patients with castration-resistant prostate cancer (CRPC). ⋯ Treatment with DOC improves OS from primary therapy compared with conventional ADT alone in Japanese patients with CRPC.